The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 286-293

  Oksefjell, Halldis ^a   Sandstad, B ^a   Trope C ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

First relapse; Ovarian cancer; Secondary cytoreduction

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; PLATINUM COMPLEX; TAXANE DERIVATIVE; THIOTEPA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; COLON SURGERY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 60649111775     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn591     Document Type: Article

References (26)

1. Cancer in Norway. Oslo, Norway: The Cancer Registry of Norway, Institute of Population-Based Cancer Research 2006.
2. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998; 69: 103-108.
3. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
4. AGO-OVAR NCIC CTG & EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl 1): 36-41.
5. Gordon AN, Tonda M, Sun S et al., on behalf of the Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
6. Ozols RF, Rubin SC, Thomas GM et al. Epithelial ovarian cancer. In Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins 2005; 895-987.
7. Harrison ML, Gore ME, Spriggs D et al. Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. Gynecol Oncol 2007; 106: 469-475.
8. Berek JS, Hacker NF, Lagasse LD et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obset Gynecol 1983; 61: 189-193.
9. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer. Nonresponders to first-line therapy. Gynecol Oncol 1989; 33: 1-5.
10. Munkarah A, Levenback C, Wolf JK et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001; 81: 237-241.
11. Zang RY, Zhang ZY, Li ZT et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 2000; 75: 24-30.
12. Bristow RE, Gossett DR, Shook DR et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002; 95: 791-800.
13. Zang RY, Li ZT, Tang J et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? Cancer 2004; 100: 1152-1156.
14. Chi DS, McCaughty K, Diaz JP et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006; 106: 1933-1939.
15. Matsumoto A, Higuchi T, Yura S et al. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J Obstet Gynaecol Res 2006; 32: 580-587.
16. Benedetti Panici P, De Vivo A, Bellati F et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007; 14: 1136-1142.
17. Santillan A, Karam AK, Li AJ et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2007; 104: 686-690.
18. Salani R, Santillan A, Zahurak ML et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: Analysis of prognostic factors and survival outcome. Cancer 2007; 109: 685-691.
19. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 2006; 13: 1702-1710.
20. Pfisterer J, Harter P, Canzler U et al. The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl 3): 195-198.
21. Tebes SJ, Sayer RA, Palmer JM et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2007; 106: 482-487.
22. Gadducci A, Iacconi P, Cosio S et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000; 79: 344-349.
23. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999; 10 (Suppl 1): 3-7.
24. Ayhan A, Gultekin M, Taskiran C et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 2006; 194: 49-56.
25. Feuer DJ, Broadley KE, Shepard JK et al. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. CD002764. Oxford, UK: Cochrane Library 2000.
26. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71 (Suppl 4): 1559-1564.